Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting | Zendy

João Morais | Zendy; Carlos Aguíar | Zendy; Euan McLeod | Zendy; Ismini Chatzitheofilou | Zendy; Isabel Fonseca Santos | Zendy; Sónia Pereira | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting

Author(s) -

João Morais,

Carlos Aguíar,

Euan McLeod,

Ismini Chatzitheofilou,

Isabel Fonseca Santos,

Sónia Pereira

Publication year - 2014

Publication title -

revista portuguesa de cardiologia

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.266

H-Index - 26

eISSN - 2174-2030

pISSN - 0870-2551

DOI - 10.1016/j.repc.2014.02.020

Subject(s) - rivaroxaban , warfarin , medicine , atrial fibrillation , cost effectiveness analysis , stroke (engine) , cost effectiveness , quality adjusted life year , aspirin , incremental cost effectiveness ratio , emergency medicine , physical therapy , risk analysis (engineering) , mechanical engineering , engineering

To project the long-term cost-effectiveness of treating non-valvular atrial fibrillation (AF) patients for stroke prevention with rivaroxaban compared to warfarin in Portugal.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research